Rezolute Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Rezolute Inc 公司

Rezolute, Inc. 是一家后期罕见病公司，专注于改善因高胰岛素血症 (HI) 引起的低血糖症患者的治疗效果。其主要临床资产 Ersodetug（原名 RZ358）是一种潜在的治疗由多种形式的高胰岛素血症引起的低血糖症的方法，包括先天性 HI 和肿瘤性 HI。Ersodetug 是一种静脉注射的人类单克隆抗体，可与胰岛素靶组织（例如肝脏、脂肪和肌肉）中胰岛素受体上的独特位点（变构）结合。先天性是一种罕见的儿科遗传性疾病，其特征是胰腺过量产生胰岛素。RZ402 是一种口服血浆激肽释放酶抑制剂 (PKI)，正在开发作为糖尿病性黄斑水肿 (DME) 慢性治疗的潜在疗法。DME 是糖尿病的血管并发症，也是失明的主要原因。RZ402 旨在阻止缓激肽的产生及其对血管渗漏和炎症的影响。

Rezolute Inc简介



公司代码RZLT

公司名称Rezolute Inc

上市日期Dec 23, 2011

CEOMr. Nevan Charles Elam, J.D.

员工数量59

证券类型Ordinary Share

年结日Dec 23

公司地址275 Shoreline Drive, Suite 500

城市REDWOOD CITY

上市交易所NASDAQ Capital Market Consolidated

国家United States of America

邮编94065

电话16502064507

网址https://www.rezolutebio.com/

公司代码RZLT

上市日期Dec 23, 2011

CEOMr. Nevan Charles Elam, J.D.

Rezolute Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Young-Jin Kim

Director

115.45K

-23.01%

Dr. Wladimir Hogenhuis, M.D.

Independent Director

58.52K

-37.09%

Dr. Sunil Karnawat

Chief Commercial Officer

12.34K

-55.03%

Dr. Nerissa C. Kreher, M.D.

Independent Director

3.08K

-91.81%

Mr. Philippe Fauchet

Independent Director

--

-100.00%

Mr. Nevan Charles Elam, J.D.

Acting Chairman of the Board, Chief Executive Officer

--

Mr. Daron Evans

Chief Financial Officer

--

Mr. Gilbert M. (Gil) Labrucherie, J.D.

Independent Director

--

Dr. Brian K. Roberts, M.D.

Chief Medical Officer

--

Mr. Erik Harris

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Young-Jin Kim

Director

115.45K

-23.01%

Dr. Wladimir Hogenhuis, M.D.

Independent Director

58.52K

-37.09%

Dr. Sunil Karnawat

Chief Commercial Officer

12.34K

-55.03%

Dr. Nerissa C. Kreher, M.D.

Independent Director

3.08K

-91.81%

Mr. Philippe Fauchet

Independent Director

--

-100.00%

Mr. Nevan Charles Elam, J.D.

Acting Chairman of the Board, Chief Executive Officer

--

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 9月26日周五

持股股东

股东类型

持股股东

占比

Federated Hermes Global Investment Management Corp.

15.45%

Fidelity Management & Research Company LLC

13.74%

Handok Inc

9.27%

Invus Public Equities LP

5.36%

The Vanguard Group, Inc.

4.43%

其他

51.75%

持股股东

占比

Federated Hermes Global Investment Management Corp.

15.45%

Fidelity Management & Research Company LLC

13.74%

Handok Inc

9.27%

Invus Public Equities LP

5.36%

The Vanguard Group, Inc.

4.43%

其他

51.75%

股东类型

持股股东

占比

Investment Advisor

34.32%

Investment Advisor/Hedge Fund

29.11%

Hedge Fund

25.42%

Corporation

9.27%

Venture Capital

2.42%

Research Firm

0.86%

Individual Investor

0.65%

Bank and Trust

0.08%

Pension Fund

0.05%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

198

83.92M

92.40%

+29.30M

2025Q2

154

54.05M

62.26%

-7.68M

2025Q1

149

54.85M

64.71%

-11.78M

2024Q4

130

52.42M

86.65%

+2.62M

2024Q3

103

45.09M

85.49%

-8.77M

2024Q2

88

47.89M

96.58%

+4.94M

2024Q1

69

35.39M

87.04%

-8.22M

2023Q4

65

37.08M

93.56%

-2.65M

2023Q3

67

32.22M

86.09%

-5.29M

2023Q2

66

32.97M

88.12%

-2.31M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Federated Hermes Global Investment Management Corp.

14.03M

15.45%

+2.76M

+24.43%

Jun 30, 2025

Fidelity Management & Research Company LLC

12.48M

13.74%

+6.19M

+98.42%

Jun 30, 2025

Handok Inc

8.42M

9.28%

+1.23M

+17.11%

Sep 22, 2025

Invus Public Equities LP

4.87M

5.36%

+4.87M

--

Sep 18, 2025

The Vanguard Group, Inc.

4.02M

4.43%

+1.65M

+69.34%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.73M

4.11%

+3.34M

+857.33%

Jun 30, 2025

Blackstone Alternative Asset Management, L.P.

3.56M

3.92%

+1.82M

+104.06%

Jun 30, 2025

UBS Financial Services, Inc.

3.04M

3.34%

+2.42M

+392.63%

Jun 30, 2025

Great Point Partners, LLC

3.03M

3.34%

+2.20M

+264.14%

Jun 30, 2025

Marshall Wace LLP

2.89M

3.18%

+1.04M

+56.43%

Jun 30, 2025

持股ETF



更新时间: 11月2日周日

机构名称

占比

ALPS Medical Breakthroughs ETF

0.5%

Invesco Dorsey Wright SmallCap Momentum ETF

0.44%

Even Herd Long Short ETF

0.28%

Fidelity Fundamental Small-Mid Cap ETF

0.21%

iShares Micro-Cap ETF

0.15%

SPDR S&P Biotech ETF

0.13%

Vanguard US Momentum Factor ETF

0.07%

Direxion Daily S&P Biotech Bull 3X Shares

0.07%

iShares Russell 2000 Growth ETF

0.04%

ProShares Hedge Replication ETF

0.03%

ALPS Medical Breakthroughs ETF

占比0.5%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.44%

Even Herd Long Short ETF

占比0.28%

Fidelity Fundamental Small-Mid Cap ETF

占比0.21%

iShares Micro-Cap ETF

占比0.15%

SPDR S&P Biotech ETF

占比0.13%

Vanguard US Momentum Factor ETF

占比0.07%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.07%

iShares Russell 2000 Growth ETF

占比0.04%

ProShares Hedge Replication ETF

占比0.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据